论文部分内容阅读
[目的]探讨白介素-11联合地塞米松治疗慢性特发性血小板减少性紫癜的起效时间及血小板变化情况。[方法]选取某院2006年1月～2010年1月住院治疗的90例慢性特发性血小板减少性紫癜患者作为研究对象,随机分为3组各30例,其中A组采用白介素-11进行治疗,B组采用地塞米松进行治疗,C组采用白介素-11联合激素进行治疗,观察比较3组的治疗的起效时间及血小板变化情况。[结果]C组治疗后的总有效率明显高于A组、B组,且C组血小板升至正常水平所用时间明显短于A组、B组(P均﹤0.05),3组治疗后的血小板均较治疗前显著升高,其中C组升高的明显优于A组、B组,经统计学处理,组间差异有统计学意义(P均﹤0.05)。C组无皮疹、消化道及肾脏、关节的临床症状,A组、B组间临床症状消失时间比较差异无统计学意义(P﹥0.05)。3组常见的副反应主要为失眠、高血压、高血糖、继发性感染、满月脸、向心性肥胖及消化道出血等。C组的副反应的发生率明显低于A组、B组,经统计学处理,差异有统计学意义(P均﹤0.05),但A组、B组间比较差异无统计学意义(P﹥0.05)。[结论]白介素-11联合激素治疗慢性特发性血小板减少性紫癜的起效时间快,明显改善血小板功能,副反应发生率低,值得临床推广应用。
[Objective] To explore the onset time and platelet change of IL-11 combined with dexamethasone in the treatment of chronic idiopathic thrombocytopenic purpura. [Methods] Ninety patients with chronic idiopathic thrombocytopenic purpura hospitalized from January 2006 to January 2010 in our hospital were selected and randomly divided into three groups of 30 cases. Group A was treated with interleukin-11 The patients in group B were treated with dexamethasone. The patients in group C were treated with interleukin-11 combined with hormones. The onset of treatment and platelet changes were compared between the three groups. [Results] The total effective rate of group C after treatment was significantly higher than that of group A and group B. The duration of platelet up to normal level in group C was significantly shorter than that of group A and group B (all P <0.05) Platelets were significantly higher than before treatment, which C group was significantly better than the A group, B group, the statistical analysis, the difference between the groups was statistically significant (P all <0.05). Group C had no rash, clinical symptoms of digestive tract, kidneys and joints. There was no significant difference in the disappearance time of clinical symptoms between groups A and B (P> 0.05). 3 groups of common side effects mainly insomnia, hypertension, hyperglycemia, secondary infection, full moon face, central obesity and gastrointestinal bleeding. The incidence of side effects in group C was significantly lower than that in group A and group B. The difference was statistically significant (P <0.05), but there was no significant difference between group A and group B (P> 0.05). [Conclusion] Interleukin-11 combined with hormone treatment of chronic idiopathic thrombocytopenic purpura rapid onset of time, significantly improved platelet function, the incidence of side effects low, worthy of clinical application.